Theradaptive’s Chief Scientific Officer Frank Vizesi provides an overview of the company’s unique protein and how it hopes to disrupt the bone replacement market in an interview with SmartTRAK at the 2025 NASS Biologic Interventions Meeting.

Frank Vizesi, chief scientific officer of Theradaptive, discusses how the company is focused on creating a new recombinant BMP-2 to solve existing problems within the Bone Replacement Market in an interview with SmartTRAK on May 9, 2025, at the 2025 North American Spine Society (NASS) Biologics Interventions meeting in Chicago, Illinois. The company is developing a new version of recombinant BMP-2 called AMP-2, an adhesive variant of BMP-2 that retains the whole protein structure of BMP-2 and all its potency to bind to implant surfaces tightly.

Click on the following video (10:47 min) to learn more. A link to download a complete transcript of the interview is also provided below.

SmartTRAK: Hi, this is Erin Dorgan, senior analyst here at SmartTRAK. I'm here today with Frank Vizesi, chief scientific officer at Theradaptive. Thank you so much. I appreciate your time. Do you mind sharing a little more about your background and role at Theradaptive?

Frank Vizesi: Sure. Thanks for having me today. So my background, originally PhD, biomedical engineer from Sydney, Australia. Was very lucky to do my studies with the great professor, Bill Walsh, a good friend, and we still talk almost daily at this point.

My background now, I've been in the spine industry based out of San Diego, California for almost 20 years. Started off with NuVasive in the biologics R&D team there. I then left to join a spin out called SeaSpine. Ultimately I was the chief scientific officer of SeaSpine. Then we were acquired and merged with Orthofix and I became the chief scientific officer of the combined company then.

About a year ago, just a little over a year ago, I left to join a new startup called Theradaptive, the company who I've been tracking for probably about five or six years. Being in the biologic space I'm always interested to find out where the next most advanced bone graft is going to come from. I've been tracking quite a few different companies and I just sort of fell in love with the technology of Theradaptive, it's very advanced, and the team there. And decided that the best way to help bring your really advanced bone biologic product to market that can really help patients and solve problems would be to come and join the company.

It was the first time for me to join a startup, my previous background all being in publicly traded companies, but I've been having a blast.

Can you share a little bit more about the technology at Theradaptive and what they're doing?

FV: Yeah, sure. So let me start first with maybe the opportunity or the problem. So right now in the biologic space, surgeons really have a choice between ...

Want to learn more about Theradaptive and how it hopes to disrupt the bone replacement market? Click the button below to download and read the complete transcript of our exclusive interview with Frank Vizesi, CSO of Theradaptive, conducted by Erin Dorgan, SmartTRAK Sr Analyst, Spine & Bone Replacement.

SmartTRAK spoke with the Westbrook Weaver, CEO of Tempo Therapeutics, to discuss the company’s new technology, how it works and the results of the clinical work they’ve completed so far.

In the wound care space, there has always been an unmet need for a product that can provide volumetric wound filling in addition to simply closing the wound. Tempo Therapeutics is looking to utilize microporous annealed particle technology, or MAP, to address this need. In an interview with SmartTRAK, Westbrook Weaver, PhD, President and CEO of Tempo Therapeutics introduces their technology for creating a three-dimensional scaffold.

To learn more about Tempo Therapeutics, click on the following video (16:41 min). A link to download a complete transcript of the interview is also provided below.

Interview Transcript:
 

At the 2023 Annual Meeting in monumental Washington DC, the Biologic Association and the American Society of Orthopaedic Surgeons (AAOS) teamed up with American Orthopaedic Society for Sports Medicine (AOSSM) to spotlight the growing interest in and latest advancements of biologics in musculoskeletal medicine. Taking center stage and garnering attention was the idea of “biological healing” and the use of biologics in various conditions and at different points of a continuum of care.

Not surprisingly, the Biological Association focused more on autologous therapies, cell culturing and the next generation of biologics, while the AOSSM meeting explored the current use and growing trends of traditional orthobiologics in orthopedic applications. This article, which is downloadable here, is part one in a two-part series highlighting key takeaways from the Biologic Association meeting, including:

• Biologic Association Key Takeaways
• Rules of Engagement: Regulations and Needed Standards
  • “Same Surgical Procedure Exception” Guidance
  •  Standards for Autologous Orthobiologics
  • Driving Better Patient Outcomes
• Current Use of Autologous Therapies and Next Generation of Biologics
  • Current Practice
  • Next Generation of Biologics
• Notable Investigative Technologies

Although several biologics seem promising to treat musculoskeletal conditions, there is still an uphill battle for widespread use. Current challenges include ...

To download "Biologics in Musculoskeletal Medicine," Part One of the series of articles by Kimberly French, SmartTRAK's GM, Orthobiologics and Regenerative Medicine, just click the button below. Look for Part Two in this series, which will cover key takeaways from AOSSM, highlighting the current use of Orthobiologics and growing trends, in the coming weeks.

Biologics had a whopping quarter, Advanced Dressings saw strong gains and External Devices continue to show minimal gains due to traditional NPWT holding down the segment.

The global AWC market is split geographically, with the US accounting for just over half, followed by Europe and then ROW, due to the US using higher technology products and their allowed reimbursement. SmartTRAK has noted shifts in market share, largely driven by currency movements. In Q123, there was less of an impact. From Q221 to Q123, the US went from 52.6% share to 53.1%, Europe from 27.9% to 28.6% and ROW from 19.5% to 18.2%.

Among the many topics covered in detail in SmartTRAK's comprehensive Q123 Advanced Wound Care Market Recap* are:

• Complete Q123 Advanced Wound Care Market Overview
• SmartTRAK's Expert Market Analysis and Insights
• All AWC Companies' News, Revenues, Data, Charts and Market Shares
• WW Advanced Dressings: Acceleration of Continued Solid Growth
• Biologics: An Impressive Quarter
  
  • Skin Substitutes/CTPs
  • Topical Delivery/Drug
  • Collagen/Active Dressings
• External Devices: Single-use NPWT and Topical Oxygen Therapy Drive Growth
• Growth Analysis – Currency Having a Less Strong Impact
  • Growth Details for Key Companies in Q123
• Other Notable Q123 AWC Events

3M remained the global revenue leader in the Q123 WW AWC market, with Smith+Nephew (SNN) is in second place and Mölnlycke rounding out the top three,  with revenues of ...

Read the entire Q123 AWC Market Recap, including SmartTRAK's expert analysis, news, data, charts, company revenues and shares*

*These links and the complete unedited article can only be viewed by SmartTRAK subscribers to this module. For more information on SmartTRAK, including how to receive a demo and subscribe, please click the button below.